WHO: latest information on the safety of medicines and legal actions taken by regulatory authorities around the world
![Immagine News](/media/cnyhiizm/cat-4.jpg?anchor=center&mode=crop&width=722&height=442)
The WHO Pharmaceuticals Newsletter N°3, 2021 provides the latest information on the safety of medicines and legal actions taken by regulatory authorities around the world. It also provides signals based on information derived from the WHO global database of individual case safety reports, VigiBase.
Among the news, we point out the following:
Atezolizumab (indicated to treat non-small cell lung cancer, small cell lung cancer and triple-negative breast cancer): Risk of severe cutaneous adverse reactions (SCAR)
VEGF (Vascular endothelial growth factor inhibitors - indicated to treat various cancers): Risk of artery dissections and aneurysms
COVID-19 vaccine mRNA: Risk of myocarditis
Remdesivir and pancreatic toxicity (along with the response from Gilead)
Tocilizumab and pancreatitis